A key panel of the U.S. Patent and Trademark Office invalidated one of AbbVie's numerous patents protecting its top-selling Humira (adalimumab), ruling in favor of biosimilar maker Coherus Biosciences’ challenge, according to a BioPharma Dive report.

The FDA and the Centers for Disease Control and Prevention (CDC) are warning that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults.

The FDA has granted a priority review designation for Bayer’s new drug application for copanlisib for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior therapies.

Based on new data from two large clinical trials, the FDA has concluded that the type-2 diabetes medicine canagliflozin (Janssen’s Invokana [canagliflozin], Invokamet [canagliflozin/metformin hydrochloride], and Invokamet XR [extended-release canagliflozin/metformin hydrochloride]) causes an increased risk of leg and foot amputations.

The war against high drug prices is being fought state by state, according to the Wall Street Journal. Some of the toughest legislation that would control drug prices has surfaced in state legislatures, and that has not gone unnoticed by the pharmaceutical industry.

New diagnoses for two types of skin cancer have increased in recent years, according to a Mayo Clinic-led team of researchers.

Orange County, New York, has sued Purdue Pharma, Johnson & Johnson, and other drug makers, accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers, leading to the current opioid epidemic in the United States, according to a Reuters report.

A 60-second television advertisement featuring actor Danny Glover, which ran widely late last year, concerned pseudobulbar affect (PBA), a neurological condition characterized by inappropriate, uncontrolled outbursts of laughing or crying.

During a conference call with health care organizations on Monday, May 15, U.S. federal officials said that several medical devices had been infected with the ransomware that recently spread across dozens of countries, but they declined to identify the devices, according to an article in the Wall Street Journal.

Meeting resistance to the House’s plans to reduce the scope and reach of Medicaid, Senate negotiators are discussing a compromise that would maintain the program’s expansion under the Patient Protection and Affordable Care Act (PPACA).

Yet more data suggesting that too much imaging can be a bad thing.

Listen to your doctor, patients have always been told and there was always an “or else’ implied.

Blue Cross Blue Shield Kansas (BCBSK) filed the initial paperwork needed to participate on the ACA exchange next year, reports KCUR 89.3 public radio. So far BCBSK, the state’s largest insurer, is the only health plan to have filed necessary paperwork.

Positive results have been announced from the ongoing phase 3 PACIFIC trial, a randomized, double-blind, placebo-controlled evaluation of durvalumab (Imfinzi, AstraZeneca/MedImmune) as sequential treatment in patients with locally advanced, unresectable (stage III) non–small-cell lung cancer (NSCLC) who had not progressed after standard platinum-based che

The American Urological Association (AUA) has released a new list of recommendations regarding specific tests or treatments that are commonly ordered but are not always necessary in urology, or urologic management that could be improved, as part of its Choosing Wisely campaign.

Pages